The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

Funda Meric-Bernstam, MD, discusses the safety of CBX-12 and exploring dosage of the agent.

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.

Elias Jabbour, MD, outlines additional findings from PhALLCON and their clinical implications for patients with Philadelphia chromosome-positive ALL

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.

Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.

Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

The nation’s top-ranked UT MD Anderson Cancer Center and flagship UT Austin to build new hospitals as part of project.

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.